Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Apr 27, 2016; 8(4): 284-293
Published online Apr 27, 2016. doi: 10.4240/wjgs.v8.i4.284
Published online Apr 27, 2016. doi: 10.4240/wjgs.v8.i4.284
NOD2 mutations and colorectal cancer - Where do we stand?
Diogo Branquinho, Paulo Freire, Carlos Sofia, Serviço de Gastrenterologia, Centro Hospitalar e Universitário de Coimbra, 3000-075 Coimbra, Portugal
Diogo Branquinho, Paulo Freire, Carlos Sofia, Faculdade de Medicina da Universidade de Coimbra, 3004-504 Coimbra, Portugal
Author contributions: Branquinho D performed the literature search and wrote the text; Freire P and Sofia C designed the text structure and made several critical corrections and revisions until the submitted version was achieved.
Conflict-of-interest statement: The above-mentioned authors of this manuscript hereby declare that they do not have any conflict-of-interest (including but not limited to commercial, personal, political, intellectual, or religious interests) related to the work submitted herein.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Diogo Branquinho, MD, Serviço de Gastroenterologia, Centro Hospitalar e Universitário de Coimbra, Praceta Professor Mota Pinto, 3000-075 Coimbra, Portugal. diogofbranquinho@yahoo.com
Telephone: +351-914-251929 Fax: +351-239-701517
Received: July 28, 2015
Peer-review started: July 31, 2015
First decision: November 6, 2015
Revised: November 20, 2015
Accepted: February 14, 2016
Article in press: February 16, 2016
Published online: April 27, 2016
Peer-review started: July 31, 2015
First decision: November 6, 2015
Revised: November 20, 2015
Accepted: February 14, 2016
Article in press: February 16, 2016
Published online: April 27, 2016
Core Tip
Core tip: Recently, data from animal models showed that nucleotide-binding and oligomerization-domain containing 2 (NOD2) deficiency leads to dysbiosis and to an increased risk of colitis and colitis-associated colorectal cancer (CRC). Furthermore, it is now known that this receptor has a much more expanded role than previously thought. Concerning population-based studies, and despite initial inconsistencies, recent data points to an important role for NOD2 mutations in CRC susceptibility. Identifying carriers of such polymorphisms may allow them to be included in stricter CRC surveillance programs. A link between NOD2 mutation carriage and response to different chemotherapy regimens is also a promising field of research.